NASDAQ: LEXX
Lexaria Bioscience Corp Stock

$1.16-0.01 (-0.85%)
Updated Apr 30, 2025
LEXX Price
$1.16
Fair Value Price
N/A
Market Cap
$20.37M
52 Week Low
$1.14
52 Week High
$4.44
P/E
-1.97x
P/B
2.85x
P/S
48.95x
PEG
N/A
Dividend Yield
N/A
Revenue
$525.92k
Earnings
-$9.38M
Gross Margin
99.5%
Operating Margin
-1,784.18%
Profit Margin
-1,784.2%
Debt to Equity
0.27
Operating Cash Flow
-$7M
Beta
0.72
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

LEXX Overview

Lexaria Bioscience Corporation is a biotech company developing a drug delivery technology, DehydraTECH, that improves the way active pharmaceutical ingredients enter the bloodstream. Dehydra being evaluated for orally administered anti-viral drugs and non-steroidal anti-inflammatory drugs. Lexaria Bioscience was incorporated in 2004 and is headquartered in Kelowna, British Columbia, Canada.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine LEXX's potential to beat the market

Zen Rating Component Grades

N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
LEXX
Ranked
Unranked of 462

Top Ranked Stocks in Industry

View Top Biotech Stocks

Be the first to know about important LEXX news, forecast changes, insider trades & much more!

LEXX News

Overview

Due Diligence Score

Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how LEXX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

LEXX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
LEXX is good value based on its book value relative to its share price (2.85x), compared to the US Biotechnology industry average (4.45x)
P/B vs Industry Valuation
LEXX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more LEXX due diligence checks available for Premium users.

Valuation

LEXX fair value

Fair Value of LEXX stock based on Discounted Cash Flow (DCF)

Price
$1.16
Fair Value
-$1.69
Undervalued by
168.63%
LEXX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

LEXX price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-1.97x
Industry
-162.28x
Market
29.18x

LEXX price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
2.85x
Industry
4.45x
LEXX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

LEXX's financial health

Profit margin

Revenue
$174.0k
Net Income
-$2.7M
Profit Margin
-1,559.3%
LEXX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
LEXX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$8.7M
Liabilities
$1.9M
Debt to equity
0.27
LEXX's short-term assets ($7.72M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
LEXX's short-term assets ($7.72M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
LEXX's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
LEXX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$1.5M
Investing
-$27.9k
Financing
$11.7k
LEXX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

LEXX vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
LEXX$20.37M-0.85%-1.97x2.85x
ALLRD$20.42M+5.26%-0.08x1.73x
LSTA$20.43M-3.23%-0.99x0.69x
PMN$20.27M+6.35%5.64x1.23x
PASG$20.26M+4.49%-0.30x0.33x

Lexaria Bioscience Stock FAQ

What is Lexaria Bioscience's quote symbol?

(NASDAQ: LEXX) Lexaria Bioscience trades on the NASDAQ under the ticker symbol LEXX. Lexaria Bioscience stock quotes can also be displayed as NASDAQ: LEXX.

If you're new to stock investing, here's how to buy Lexaria Bioscience stock.

What is the 52 week high and low for Lexaria Bioscience (NASDAQ: LEXX)?

(NASDAQ: LEXX) Lexaria Bioscience's 52-week high was $4.44, and its 52-week low was $1.14. It is currently -73.87% from its 52-week high and 1.75% from its 52-week low.

How much is Lexaria Bioscience stock worth today?

(NASDAQ: LEXX) Lexaria Bioscience currently has 17,559,179 outstanding shares. With Lexaria Bioscience stock trading at $1.16 per share, the total value of Lexaria Bioscience stock (market capitalization) is $20.37M.

Lexaria Bioscience stock was originally listed at a price of $98.19 in Feb 12, 2007. If you had invested in Lexaria Bioscience stock at $98.19, your return over the last 18 years would have been -98.82%, for an annualized return of -21.85% (not including any dividends or dividend reinvestments).

How much is Lexaria Bioscience's stock price per share?

(NASDAQ: LEXX) Lexaria Bioscience stock price per share is $1.16 today (as of Apr 30, 2025).

What is Lexaria Bioscience's Market Cap?

(NASDAQ: LEXX) Lexaria Bioscience's market cap is $20.37M, as of May 1, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Lexaria Bioscience's market cap is calculated by multiplying LEXX's current stock price of $1.16 by LEXX's total outstanding shares of 17,559,179.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.